We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SN.LSE

Price
1079.50
Stock movement up
+5.50 (0.51%)
Company name
Smith & Nephew PLC
Exchange
(LSE
,
Currency
GBX
)
Sector
Healthcare >
Medical Devices
Markedsværdi
941.30B
Ent værdi
946.07B
Pris/omsætning
222.29
Pris/bog
180.85
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
144.41%
Efterfølgende P/E
3627.37
Fremtidig P/E
1102.99
PEG
-
EPS-vekst
-16.87%
1 års afkast
7.41%
3 års afkast
-2.16%
5 års afkast
-7.68%
10 års afkast
0.05%
Senest opdateret: 2025-06-22

UDBYTTE

SN.LSE betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E3627.37
Pris til OCF1938.83
Pris til FCF5129.72
Pris til EBITDA1148.63
EV i forhold til EBITDA1154.45

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning222.29
Pris til egenkapital180.85
EV i forhold til salg223.42

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier871.98M
EPS (TTM)0.30
FCF pr. aktie (TTM)0.21

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)4.23B
Bruttofortjeneste (TTM)2.97B
Driftsindkomst (TTM)531.50M
Nettoindkomst (TTM)259.50M
EPS (TTM)0.30
EPS (1 år frem)0.98

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)70.16%
Driftsmargin (TTM)12.55%
Fortjenstmargin (TTM)6.13%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter568.00M
Nettotilgodehavender1.35B
Omsætningsaktiver i alt4.46B
Goodwill3.10B
Immaterielle aktiver1.11B
Ejendomme, anlæg og udstyr0.00
Sum aktiver10.54B
Kreditor1.02B
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser1.78B
Sum gæld5.34B
Aktionærernes egenkapital5.21B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)485.50M
Investeringsudgifter (TTM)302.00M
Fri pengestrøm (TTM)183.50M
Udbetalt udbytte (TTM)265.00M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast4.99%
Afkast af aktiver2.46%
Afkast af investeret kapital3.11%
Kontant afkast af investeret kapital2.20%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning1077.00
Daglig høj1089.00
Daglig lav1072.50
Daglig volumen4.09M
Højeste gennem alle tider1990.00
1 års analytiker estimat1256.69
Beta0.70
EPS (TTM)0.30
Udbytte pr. aktie-
Ex-div dato27 Mar 2025
Næste dato for resultatpræsentation5 Aug 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
SN.LSES&P500
Nuværende prisfald fra top notering-45.75%-3.04%
Højeste prisfald-54.96%-56.47%
Højeste efterår dato27 Oct 20239 Mar 2009
Gennemsnitlig fald fra toppen-15.00%-11.04%
Gennemsnitlig tid til nyt højdepunkt32 days12 days
Maks. tid til nyt højdepunkt1465 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
SN.LSE (Smith & Nephew PLC) company logo
Markedsværdi
941.30B
Markedsværdi kategori
Large-cap
Beskrivelse
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Personale
18000
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
UK
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Ingen varer fundet